US FDA approves Incyte's eczema treatment for pediatric patients

ReutersSep 18, 2025 8:25 PM

Sept 18 (Reuters) - The U.S. Food and Drug Administration has approved Incyte's INCY.O eczema treatment for children aged between 2 and 11 years, the company said on Thursday.

It was previously approved for individuals aged 12 years and older.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

TradingKey - Oil prices surge as US-Iran clashes resume following a brief de-escalation.

Today’s Market Recap: AI Leadership Shifts and Macro Policy Jitters Drive Market Volatility

US stocks closed mixed, while the AI industry landscape underwent dramatic changes: Anthropic's valuation surpassed OpenAI's, marking a shift towards its xAI strategy. Geopolitical and tariff rulings triggered volatility, causing CoreWeave to plummet after its earnings report.

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

TradingKey - During the US market opening session on May 7, Tesla (TSLA.US) shares extended their rebound momentum, rising more than 2% at one point to open at $406, returning above the $400 level. On May 5 and 6, the stock touched the $400 mark intraday but closed below that threshold on both days.

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

TradingKey - On Wednesday (May 7), Anthropic reached an agreement with Elon Musk's SpaceX to access SpaceX's massive data center 'Colossus 1.' Meanwhile, Musk announced that xAI would be dissolved as an independent company and renamed SpaceXAI, becoming an AI product line within SpaceX. Can SpaceX's

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools